TCM

TCG Crossover Management Portfolio holdings

AUM $4.16B Turnover 31.15%
1-Year Est. Return 983.43%
This Fund
S&P 500
This Quarter Est. Return
+25.95%
1 Year Est. Return
+983.43%
3 Year Est. Return
+3,012.95%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.16B
AUM Growth
+$665M
Cap. Flow
-$4.87M
Cap. Flow %
-0.12%
Top 10 Hldgs %
57.45%
Holding
61
New
12
Increased
2
Reduced
9
Closed
7
Avg Time Held
1 year
Top 10 Avg Time Held
0.8 years
Top 20 Avg Time Held
1.3 years

Top Buys

Rank Stock Value
1
ZLAB icon
Zai Lab
ZLAB
+$121M
2
AURA icon
Aura Biosciences
AURA
+$68.2M
3
TRAX icon
First Tracks Biotherapeutics
TRAX
+$54.1M
4
AVTX icon
Avalo Therapeutics
AVTX
+$36M
5
EDIT icon
Editas Medicine
EDIT
+$32.5M

Top Sells

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$170M
2
ABVX icon
Abivax
ABVX
+$53.6M
3
FULC icon
Fulcrum Therapeutics
FULC
+$40.3M
4
TNGX icon
Tango Therapeutics
TNGX
+$35.8M
5
RVMD icon
Revolution Medicines
RVMD
+$34.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.82%
2 Financials 0.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ABVX icon
1
Abivax
ABVX
$7.68B
$801M 19.24%
6,007,834
-473,251
-7% -$53.6M
2023 Q4
10 quarters
TNGX icon
2
Tango Therapeutics
TNGX
$3.74B
$284M 6.82%
9,081,201
-1,449,870
-14% -$35.8M
2024 Q4
6 quarters
CGON icon
3
CG Oncology
CGON
$5.48B
$261M 6.27%
3,670,206
– –
2024 Q1
9 quarters
COGT icon
4
Cogent Biosciences
COGT
$4.88B
$188M 4.52%
4,854,436
-92,458
-2% -$3.23M
2021 Q4
18 quarters
IMVT icon
5
Immunovant
IMVT
$5.76B
$172M 4.13%
4,457,988
– –
2025 Q4
2 quarters
SYRE icon
6
Spyre Therapeutics
SYRE
$7.35B
$169M 4.06%
1,900,582
– –
2025 Q3
3 quarters
DNTH icon
7
Dianthus Therapeutics
DNTH
$4.18B
$163M 3.93%
1,676,624
– –
2024 Q4
6 quarters
MIRM icon
8
Mirum Pharmaceuticals
MIRM
$5.19B
$124M 2.99%
1,062,049
– –
2025 Q4
2 quarters
ZLAB icon
9
Zai Lab
ZLAB
$2.53B
$117M 2.8%
+6,137,627
New +$121M
2026 Q2
0 quarters
AMLX icon
10
Amylyx Pharmaceuticals
AMLX
$3.39B
$112M 2.7%
6,243,812
– –
2024 Q3
7 quarters
GLUE icon
11
Monte Rosa Therapeutics
GLUE
$839M
$112M 2.69%
4,622,151
– –
2025 Q4
2 quarters
BCRX icon
12
BioCryst Pharmaceuticals
BCRX
$2.06B
$110M 2.65%
11,020,968
– –
2026 Q1
1 quarter
VOR icon
13
Vor Biopharma
VOR
$1.11B
$104M 2.51%
5,673,078
– –
2026 Q1
1 quarter
TYRA icon
14
Tyra Biosciences
TYRA
$1.29B
$104M 2.49%
3,248,980
– –
2021 Q4
18 quarters
DYN icon
15
Dyne Therapeutics
DYN
$2.81B
$103M 2.46%
4,615,144
– –
2023 Q1
13 quarters
IRON icon
16
Disc Medicine
IRON
$2.14B
$98.1M 2.36%
1,341,862
– –
2026 Q1
1 quarter
RLAY icon
17
Relay Therapeutics
RLAY
$3.74B
$80M 1.92%
4,273,356
– –
2025 Q3
3 quarters
SVRA icon
18
Savara
SVRA
$978M
$76.2M 1.83%
12,362,205
– –
2023 Q3
11 quarters
AURA icon
19
Aura Biosciences
AURA
$640M
$67.7M 1.63%
+9,533,333
New +$68.2M
2026 Q2
0 quarters
RVMD icon
20
Revolution Medicines
RVMD
$41.5B
$63.8M 1.53%
340,899
-235,574
-41% -$34.4M
2025 Q3
3 quarters
TRAX icon
21
First Tracks Biotherapeutics
TRAX
$1.22B
$58.3M 1.4%
+2,895,304
New +$54.1M
2026 Q2
0 quarters
KOD icon
22
Kodiak Sciences
KOD
$5.1B
$56.3M 1.35%
1,445,538
– –
2023 Q4
10 quarters
AVTX icon
23
Avalo Therapeutics
AVTX
$635M
$55.8M 1.34%
3,017,120
+2,278,737
+309% +$36M
2024 Q3
7 quarters
LBRX icon
24
LB Pharmaceuticals
LBRX
$1.1B
$47M 1.13%
1,447,310
-392,179
-21% -$11.5M
2025 Q3
3 quarters
IPSC icon
25
Century Therapeutics
IPSC
$250M
$43.4M 1.04%
17,754,430
– –
2026 Q1
1 quarter
1
2 3

Similar funds

GCM
Gates Capital Management New York $4.16B AUM 21% 1-Year Est. Return
CIC
Chilton Investment Company Stamford, Connecticut $4.17B AUM 1.75% 1-Year Est. Return
LWCA
Locust Wood Capital Advisers New York $4.15B AUM 31.06% 1-Year Est. Return
CWG
C WorldWide Group Copenhagen, Denmark $4.15B AUM 13.14% 1-Year Est. Return
MSI
Mitsui Sumitomo Insurance Tokyo, Japan $4.15B AUM
CAM
Crake Asset Management London, United Kingdom $4.18B AUM 13.97% 1-Year Est. Return
JFG
JMG Financial Group Downers Grove, Illinois $4.14B AUM 21.49% 1-Year Est. Return
CCMIC
Cardinal Capital Management Inc (Canada) Winnipeg, Manitoba, Canada $4.13B AUM 31.23% 1-Year Est. Return

TCG Crossover Management's Q2 2026 Portfolio in Review

As of Q2 2026, TCG Crossover Management held 61 positions worth $4.16B, up 19% from $3.5B the previous quarter. Its ten largest holdings account for 57% of the portfolio.

TCG Crossover Management's Q2 2026 filing shows 12 new, 2 increased, 9 reduced and 7 closed positions. Its largest new stake was Zai Lab: 6,137,627 shares worth $117M. The largest sale was Centessa Pharmaceuticals, an estimated $170M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

  • TCG Crossover Management's largest Q2 2026 buy was Zai Lab: 6,137,627 shares worth $117M.
  • TCG Crossover Management added most to Avalo Therapeutics in Q2 2026, an estimated $36M increase.
  • TCG Crossover Management's biggest Q2 2026 reduction was Abivax, cutting an estimated $53.6M.
  • TCG Crossover Management fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $170M.
  • TCG Crossover Management's ten largest holdings make up 57% of its $4.16B portfolio in Q2 2026.
  • TCG Crossover Management opened 12 new positions and closed 7 in Q2 2026.
  • TCG Crossover Management's portfolio value rose 19% quarter-over-quarter to $4.16B.

Based on TCG Crossover Management's 13F filing for Q2 2026, filed 14 Aug 2026.